The use of expensive technologies instead of simple, sound and effective lifestyle interventions: A perpetual delusion

Journal of Epidemiology and Community Health

Volumn 68, Issue 9, 2014, Pages 897-904

  Carlos, Silvia ^a,b   de Irala, Jokin ^a,b,c   Hanley, Matt ^a   Martínez González, Miguel ángel ^a,c  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASES; DECISION MAKING; DIABETES MELLITUS, TYPE 2; ECONOMICS; HUMAN; LIFESTYLE; NEOPLASMS; OBESITY; PAPILLOMAVIRUS INFECTIONS; PRIMARY PREVENTION; PUBLIC HEALTH; RISK REDUCTION; TECHNOLOGY;

CARDIOVASCULAR DISEASES; DECISION MAKING; DIABETES MELLITUS, TYPE 2; HUMANS; LIFE STYLE; NEOPLASMS; OBESITY; PAPILLOMAVIRUS INFECTIONS; PRIMARY PREVENTION; PUBLIC HEALTH; RISK REDUCTION BEHAVIOR; TECHNOLOGY;

EID: 84905393352     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech-2014-203884     Document Type: Article

References (106)

1. US Burden of Disease Collaborators. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013;310:591-608.
2. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study Lancet 2012;380:2224-60.
3. Anonimous. The catastrophic failures of public health. Lancet 2004;363:745.
4. Brezis M, Wiist WH. Vulnerability of health to market forces. Med Care 2011;49:232-9.
5. Nichols M, Townsend N, Scarborough P, et al. European Cardiovascular Disease Statistics 2012. Sophia Antipolis: European Heart Network and European Society of Cardiology, 2012.
6. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 Nov 7. pii: S0735-1097(13) 06028-2. doi:10.1016/j.jacc.2013.11.002
7. Malhotra A. Saturated fat is not the major issue. BMJ 2013;347:f6340.
8. Sinatra ST, Teter BB, Bowden J, et al. The saturated fat, cholesterol, and statin controversy a commentary. J Am Coll Nutr 2014;33:79-88.
9. Singh GM, Danaei G, Farzadfar F, et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One 2013;8:e65174.
10. Ioannidis JP. More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. JAMA 2014;311:463-4.
11. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med 2014;370:1422-31.
12. Anonimous. Statins for millions more? Lancet 2014;383:669.
13. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013;382:1762-5.
14. Reiner Z. Polypill is not a 'vaccine-like' solution for primary cardiovascular disease prevention in all parts of the world. J Epidemiol Community Health 2013;67:981-2.
15. Perlmutter D, Golomb B, Sinatra S, et al. Appropriate clinical use of statins: a discussion of the evidence, scope, benefits, and risk. Altern Ther Health Med 2013;19(Suppl 1):14-25.
16. World Health Organization. Cardiovascular diseases. Fact sheet No317. Updated March 2013.
17. Mascitelli L, Goldstein MR. Statin and exercise prescription. Lancet 2013;381:1622.
18. Martínez-González Má, Corella D, Salas-Salvadó J, et al. Cohort profile: design and methods of the PREDIMED study. Int J Epidemiol 2012;41:377-85.
19. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368:1279-90.
20. Ruiz-Canela M, Estruch R, Corella D, et al. Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial. JAMA 2014;311:415-17.
21. Martínez-Gonzalez MA, Toledo E, Aros F, et al. Extra-virgin olive oil consumption reduces risk of atrial fibrillation: the PREDIMED trial. Circulation 2014 Apr 30. [Epub ahead of print]
22. Gea A, Bes-Rastrollo M, Toledo E, et al. Mediterranean alcohol-drinking pattern and mortality in the SUN (Seguimiento Universidad de Navarra) Project: a prospective cohort study. Br J Nutr 2014;111:1871-80.
23. Testino G, Patussi V, Scafato E, et al. Alcohol, cardiovascular disease and cancer. Alcohol Alcohol 2013;48:627-8.
24. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for and 2030. Diabetes Res Clin Pract 2010;87:4-14.
25. Beagley J, Guariguata L, Weil C, et al. Global estimates of undiagnosed diabetes in adults for 2013. Diabetes Res Clin Pract 2014;103:150-60.
26. Zimmet PZ, Magliano DJ, Herman WH, et al. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2014;2:56-64.
27. Ley SH, Hamdy O, Mohan V, et al. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet 2014;383:1999-2007.
28. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Eng J Med 2001;345:790-7.
29. Danaei G, Pan A, Hu FB, et al. Hypothetical midlife interventions in women and risk of type 2 diabetes. Epidemiology 2013;24:122-8.
30. Salas-Salvadó J, Bulló M, Estruch R, et al. Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. Ann Intern Med 2014;160:1-10.
31. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
32. Knowler WC, Fowler SE, Hamman RF, et al.; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-86.
33. Florez H, Temprosa MG, Orchard TJ, et al. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes Obes Metab 2014;16:326-33.
34. Goldberg R, Temprosa M, Otvos J, et al. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab 2013;98:3989-98.
35. Davis NJ, Ma Y, Delahanty LM, et al. Predictors of sustained reduction in energy and fat intake in the Diabetes Prevention Program Outcomes Study intensive lifestyle intervention. J Acad Nutr Diet 2013;113:1455-64.
36. Cleland JG, Atkin SL. Thiazolidinediones, deadly sins, surrogates, and elephants. Lancet 2007;370:1103-4.
37. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs-insights from the rosiglitazone experience. N Engl J Med 2013;369:1285-7.
38. Tucker ME. FDA panel advises easing restrictions on rosiglitazone. BMJ 2013;346: f3769.
39. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301.
40. Martinez-Gonzalez MA, Bes-Rastrollo M. Dietary patterns, Mediterranean diet, and cardiovascular disease. Curr Opin Lipidol 2014;25:20-6.
41. Salas-Salvadó J, Martinez-González Má, Bulló M, et al. The role of diet in the prevention of type 2 diabetes. Nutr Metab Cardiovasc Dis 2011;21(Suppl 2): B32-48.
42. Hamer M. Physical activity and health: MMXII. J Epidemiol Community Health 2012;66:665-6.
43. Heath GW, Parra DC, Sarmiento OL, et al. Evidence-based intervention in physical activity: lessons from around the world. Lancet 2012;380:272-81.
44. World Health Organization. Physical activity. Fact sheet No 384. February 2014.
45. Hallal PC, Andersen LB, Bull FC, et al.; Lancet Physical Activity Series Working Group. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet 2012;380:247-57.
46. Sibai AM, Costanian C, Tohme R, et al. Physical activity in adults with and without diabetes: from the 'high-risk' approach to the 'population-based' approach of prevention. BMC Public Health 2013;13:1002.
47. Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr 2012;10:22.
48. World Health Organization. Obesity and overweight. Fact sheet No 311 Updated March 2013.
49. Bibiloni MD, Pons A, Tur JA. Prevalence of overweight and obesity in adolescents: a systematic review. ISRN Obes 2013;2013:392747.
50. Gordon-Larsen P, Wang H, Popkin BM. Overweight dynamics in Chinese children and adults. Obes Rev 2014;15(Suppl 1):37-48.
51. Willett WC, Stampfer MJ. Current evidence on healthy eating. Annu Rev Public Health 2013;34:77-95.
52. de Onis M, Blössner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr 2010;92:1257-64.
53. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014;311:806-14.
54. Cunningham SA, Kramer MR, Narayan KM. Incidence of childhood obesity in the United States. N Engl J Med 2014;370:403-11.
55. Zhang ZY, Wang MW. Obesity, a health burden of a global nature. Acta Pharmacol Sin 2012;33:145-7.
56. Morrato EH, Allison DB. FDA approval of obesity drugs: a difference in risk-benefit perceptions. JAMA 2012;308:1097-8.
57. Lagerros YT, Rössner S. Obesity management: what brings success? Therap Adv Gastroenterol 2013;6:77-88.
58. Kirk SF, Penney TL. The role of health systems in obesity management and prevention: problems and paradigm shifts. Curr Obes Rep 2013;2:315-9.
59. Katan MB. Weight-loss diets for the prevention and treatment of obesity. N Engl J Med 2009;360:923-5.
60. Blundell JE, Stubbs RJ, Golding C, et al. Resistance and susceptibility to weight gain: individual variability in response to a high-fat diet. Physiol Behav 2005;86:614-22.
61. Parkin DM, Boyd L, Walker LC. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer 2011;105(Suppl 2):S77-81.
62. Espina C, Porta M, Schüz J, et al. Environmental and occupational interventions for primary prevention of cancer: a cross-sectorial policy framework. Environ Health Perspect 2013;121:420-6.
63. Schottenfeld D, Beebe-Dimmer JL, Buffler PA, et al. Current perspective on the global and United States cancer burden attributable to lifestyle and environmental risk factors. Annu Rev Public Health 2013;34:97-117.
64. Dartois L, Fagherazzi G, Boutron-Ruault MC, et al. Association between five lifestyle habits and cancer risk: Results from the E3N cohort. Cancer Prev Res (Phila) 2014;7:516-25.
65. Stewart BW, Wild CP. World Cancer Report 2014. Lyon: International Agency for Research on Cancer, 2014.
66. World Health Organization. Public Health round-up. Countries need cancer prevention. Bull World Health Organ 2014;92:157.
67. Chalkidou K, Marquez P, Dhillon PK, et al. Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. Lancet Oncol 2014;15:e119-31.
68. Moyer VA. Screening for lung cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2014;160:330-8.
69. Vineis P, Wild CP. Global cancer patterns: causes and prevention. Lancet 2014;383:549-57.
70. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013;368:341-50.
71. Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 2014;311:183-92.
72. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981;66:1191-308.
73. Varmus H, Kumar HS. Addressing the growing international challenge of cancer: a multinational perspective. Sci Transl Med 2013;5:175.
74. Rigotti NA. Smoking cessation in patients with respiratory disease: existing treatments and future directions. Lancet Respir Med 2013;1:241-50.
75. Holford TR, Meza R, Warner KE, et al. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. JAMA 2014;311:164-71.
76. Jha P. The 21st century benefits of smoking cessation in Europe. Eur J Epidemiol 2013;28:617-19.
77. Moyer VA; U.S. Preventive Services Task Force. Primary care interventions to prevent tobacco use in children and adolescents: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:552-7.
78. Dunlop SM, Perez D, Cotter T. Australian smokers' and recent quitters' responses to the increasing price of cigarettes in the context of a tobacco tax increase. Addiction 2011;106:1687-95.
79. World Health Organization. WHO Report on the global tobacco epidemic. Enforcing bans on tobacco advertising, promotion and sponsorship. Luxembourg, 2013.
80. Thrift AP, Whiteman DC. Can we really predict risk of cancer? Cancer Epidemiol 2013;37:349-52.
81. Smith SC Jr. Reducing the global burden of ischemic heart disease and stroke: a challenge for the cardiovascular community and the United Nations. Circulation 2011;124:278-9.
82. Lilly CL, Gebremariam YD, Cottrell L, et al. Trends in serum lipids among 5th grade CARDIAC participants, 2002-2012. J Epidemiol Community Health 2014;68:218-23.
83. Kontis V, Mathers CD, Rehm J, et al. Contribution of six risk factors to achieving the 25×25 non-communicable disease mortality reduction target: a modelling study. Lancet 2014 May 2. pii: S0140-6736(14)60616-4. doi: 10.1016/S0140- 6736(14)60616-4. [Epub ahead of print].
84. Stephens S, Cobiac L, Veerman L. Improving diet and physical activity to reduce population prevalence of overweight and obesity: An overview of current evidence. Prev Med 2014;62:167-78.
85. James WP. Obesity-a modern pandemic: the burden of disease. Endocrinol Nutr 2013;60(Suppl 1):3-6.
86. Phillips G, Bottomley C, Schmidt E, et al. Measures of exposure to the Well London Phase-1 intervention and their association with health well-being and social outcomes. J Epidemiol Community Health, 2014;68:597-605.
87. Bourke M, Whittaker PJ, Verma A. Are dietary interventions effective at increasing fruit and vegetable consumption among overweight children? A systematic review. J Epidemiol Community Health 2014;68:485-90.
88. Laverack G. Improving health outcomes through community empowerment: a review of the literature. J Health Popul Nutr 2006;24:113-20.
89. O'Malley PG. On motivating patients: a picture, even if worth a thousand words, is not enough. Arch Intern Med 2012;172:309-10.
90. Smith SC Jr, Chen D, Collins A, et al. Moving from political declaration to action on reducing the global burden of cardiovascular diseases: a statement from the Global Cardiovascular Disease Taskforce. J Am Coll Cardiol 2013;62:2151-3.
91. Penney TL, Almiron-Roig E, Shearer C, et al. Modifying the food environment for childhood obesity prevention: challenges and opportunities. Proc Nutr Soc 2014;15:1-11.
92. Stark JH, Neckerman K, Lovasi GS, et al. Neighbourhood food environments and body mass index among New York City adults. J Epidemiol Community Health 2013;67:736-42.
93. Haughton B, Stang J. Population risk factors and trends in health care and public policy. J Acad Nutr Diet 2012;112(3 Suppl):S35-46.
94. Melendez Carrera P. The difficulty of making healthy choices and 'health in all policies'. Bull World Health Organ 2014;92:154.
95. Schmidt LA. New unsweetened truths about sugar. JAMA Intern Med 2014;174:525-6.
96. Martínez-González MA, Carlos S, de Irala J. [Human papillomavirus vaccine: optimism versus prudence]. Med Clin (Barc) 2008;131:256-63.
97. Haug CJ. Human papillomavirus vaccination-reasons for caution. N Eng J Med 2008;359:861-2.
98. Pons-Salort M, Thiébaut AC, Guillemot D, et al. HPV genotype replacement: too early to tell. Lancet Infect Dis 2013;13:1012.
99. Hopkins TG, Wood N. Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes. Vaccine 2013;31:1673-9.
100. Wise J. Young women most at risk are least likely to be offered HPV vaccine. BMJ 2014;348:g2190.
101. Garland SM, Brown DR. Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer. Expert Opin Biol Ther 2014;14:527-34.
102. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction -the first five years. Vaccine 2012;30(Suppl 5):F139-48.
103. Kim JJ. The role of cost-effectiveness in U.S. vaccination policy. N Engl J Med 2011;365:1760-1.
104. Rose G. The strategy of preventive medicine. London: Oxford University Press, 1994.
105. Stuckler D, Siegel K. Sick societies: responding to the global challenge of chronic disease. New York, NY: Oxford University Press, 2011.
106. Rodríguez-Rieiro C, Aragonés N, Pollan M, et al. Temporal trends of cervical cancer mortality rates among regions in Spain: 1975-2004. Med Clin (Barc) 2009;133:41-6.